Genmab — Januar 2024
-
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer – Alligator Bioscience
Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...
(alligatorbioscience.se)
-
That would actually be a very high premium for a takeover right now
-
-
Agree E L
-
w Her er definitionen på stilleperioden. Jeg kunne ikke finde den på dansk. https://www.investopedia.com/terms/q/quietperiod.asp
-
-
Genmab: Observe quiet periods two weeks before issuing financial reports with no broad discussions with investors and financial analysts. https://ir.genmab.com/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind